Showing results (71-80 of 79) with videos related to
Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2014
PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancerSibylle Loibl, Gunter von Minckwitz, Andreas Schneeweiss, et al.The Lancet. Oncology|May 6, 2014
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trialGunter von Minckwitz, Andreas Schneeweiss, Sibylle Loibl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto StudyPeter A Fasching, Sibylle Loibl, Chunling Hu, et al.International Journal of Cancer|January 30, 2019
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trialMelanie Janning, Volkmar Müller, Eik Vettorazzi, et al.European Journal of Cancer (Oxford, England : 1990)|March 20, 2021
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trialsSonia L Villegas, Valentina Nekljudova, Nicole Pfarr, et al.International Journal of Cancer|June 24, 2015
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto studyAlexander Hein, Diether Lambrechts, Gunter von Minckwitz, et al.Breast Care (Basel, Switzerland)|December 7, 2016
Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyPaul Gaß, Peter A Fasching, Tanja Fehm, et al.Integrative Cancer Therapies|September 16, 2016
Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM StudyCarolin C Hack, Peter A Fasching, Tanja Fehm, et al.BMC Cancer|June 23, 2019
Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM studyMarkus Wallwiener, Naiba Nabieva, Manuel Feisst, et al.Pageof 8